Data compiled by Redley Lamar · ChainSifter Intelligence
4Suppliers
7Customers
3Debt Items
20Related Chains
Source-Backed Evidence Depth
Equillium, Inc. (EQ) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
15Total relationships
4Distinct source URLs
7High confidence
0.777Average confidence
2026-10-28Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.
Equillium, Inc. Suppliers
Ticker
Name
Confidence
Evidence
ARIAGEN-INC
ARIAGEN-INC
90%
In October 2024, we acquired Ariagen, Inc., or Ariagen, to obtain exclusive, worldwide rights to EQ504, a potent and selective AhR modulator.
BIONIZ-THERAPEUTICS-INC
BIONIZ-THERAPEUTICS-INC
90%
We also acquired the exclusive worldwide rights to EQ302, a proprietary platform for discovering additional, novel multi-cytokine targeting product candidates through the acquisition of Bioniz Therap…
SNYNF
Sanofi
72%
Reciprocal relationship from SNYNF graph: Reciprocal relationship from EQ graph: rotagonist Therapeutics, Inc., Sanofi SA, Takeda Pharmaceuticals, Teva Pharmaceuticals, Topas Therapeutics GmbH, and Z…
SNYNF
Sanofi
72%
rotagonist Therapeutics, Inc., Sanofi SA, Takeda Pharmaceuticals, Teva Pharmaceuticals, Topas Therapeutics GmbH, and Zedira GmbH. Sales and Marketing Given our stage of development, we have not yet e…
Equillium, Inc. Customers
Ticker
Name
Confidence
Evidence
COLLABORATION-PARTNER
COLLABORATION-PARTNER
90%
From 2022 to 2024, we generated revenue from an upfront payment and development funding related to an asset purchase agreement with a collaboration partner.
SNYNF
Sanofi
72%
rotagonist Therapeutics, Inc., Sanofi SA, Takeda Pharmaceuticals, Teva Pharmaceuticals, Topas Therapeutics GmbH, and Zedira GmbH. Sales and Marketing Given our stage of development, we have not yet e…
SNYNF
Sanofi
72%
Reciprocal relationship from SNYNF graph: Reciprocal relationship from EQ graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from EQ graph: Reciprocal relationship from SNYNF gr…
ATTENUATE-BIOPHARMACEUTICALS-INC
ATTENUATE-BIOPHARMACEUTICALS-INC
62%
expired at the end of 2025, which, among other provisions in the law, are anticipated to reduce the number of Americans with health insurance. The OBBBA also is expected to reduce Medicaid spending a…
BIONIZ-THERAPEUTICS-INC
BIONIZ-THERAPEUTICS-INC
62%
expired at the end of 2025, which, among other provisions in the law, are anticipated to reduce the number of Americans with health insurance. The OBBBA also is expected to reduce Medicaid spending a…
DEVELOPMENT-TAX-INCENTIVE-EQUILLIUM-AUSTRALIA-PT
DEVELOPMENT-TAX-INCENTIVE-EQUILLIUM-AUSTRALIA-PT
62%
mated to approximate the interest rate on a collateralized basis with similar terms and payments, and in similar economic environments. Lease expense for lease payments is recognized on a straight-li…
Reciprocal relationship from VYGR graph: Reciprocal relationship from EQ graph: Reciprocal relationship from VYGR graph: Reciprocal relationship from EQ graph: Reciprocal relationship from VYGR graph…
Equillium, Inc. Debt Obligations
Instrument
Description
Confidence
Evidence
EQ-DEBT-9341
Xbrl Convertible
90%
xbrl convertible detail from xbrl 2018-12-31.
EQ-DEBT-9340
Warrants outstanding: 266000
90%
xbrl warrant detail from xbrl 2019-12-31.
EQ-DEBT
Debt stack $7.6M
90%
Market cache reports total debt of $7.6M.
Equillium, Inc. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for Equillium, Inc..
Equillium, Inc. Ownership
Holder
Name
Confidence
Evidence
EQ-OWNER-JANUS-HENDERSON-GROUP-PLC
JANUS HENDERSON GROUP PLC
90%
13F overlay lists JANUS HENDERSON GROUP PLC as top holder; 51 tracked holders.
